FAQ: Tonix Pharmaceuticals Appoints Jim Hunter to Board of Directors and Advances in Biopharmaceutical Innovations
Summary
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has appointed Jim Hunter to its Board of Directors, leveraging his commercial expertise as the company prepares for the potential launch of TNX-102 SL for fibromyalgia, marking a significant step in its biopharmaceutical advancements.
Who has Tonix Pharmaceuticals recently appointed to its Board of Directors?
Tonix Pharmaceuticals has appointed James ‘Jim’ Hunter to its Board of Directors, effective June 12. Hunter previously served as Executive Vice President, Commercial, where he built the Company’s commercial subsidiary, Tonix Medicines, and led its entry into the migraine market.
What is the significance of Jim Hunter’s appointment to Tonix Pharmaceuticals’ Board of Directors?
Jim Hunter’s operational insight and commercial expertise are seen as key assets for Tonix Pharmaceuticals as it prepares for a potential launch of TNX-102 SL for fibromyalgia later this year, highlighting the company’s focus on strengthening its leadership for upcoming product launches.
What is TNX-102 SL and what is its current status?
TNX-102 SL is a product candidate for the management of fibromyalgia, for which two statistically significant phase 3 studies have been completed. The FDA has granted Fast Track designation to TNX-102 SL, and Tonix’s priority is to submit a New Drug Application (NDA) to the FDA this month.
What other developments are part of Tonix Pharmaceuticals’ portfolio?
Tonix Pharmaceuticals’ development portfolio includes TNX-1300 for cocaine intoxication, TNX-1500 for preventing allograft rejection and treating autoimmune diseases, and TNX-4200, a small molecule broad-spectrum antiviral agent. The company also markets products for acute migraine treatment.
Where can I find more information about Tonix Pharmaceuticals and its latest updates?
More information about Tonix Pharmaceuticals can be found on their website at www.TonixPharma.com, and the latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
What is the focus of Tonix Pharmaceuticals’ research and development?
Tonix Pharmaceuticals focuses on transforming therapies for pain management, modernizing solutions for public health challenges, and developing treatments for CNS disorders, immunology, rare diseases, and infectious diseases.
Has Tonix Pharmaceuticals received any recent contracts or awards?
Yes, the U.S. Department of Defense, Defense Threat Reduction Agency awarded Tonix Pharmaceuticals a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections in biological threat environments.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 109005